Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kwan Lee

Interventional Cardiology Scottsdale, AZ Medical Doctor

NPI 1417931965 CMS profile 336061

13400 E Shea Blvd, Scottsdale, AZ 85259

Open in the dashboard

General payments

$11,508

130 records reported · program years 2019–2025

Research payments

$3,200

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$25,000

1 holding reported · through program year 2025

Research they led as principal investigator

$41,110 paid to institutions, not to them · program year 2019

Through program year 2025, Kwan Lee of Scottsdale, AZ is reported in the CMS Open Payments database as having received $11,508 across 130 general payments and $3,200 in research payments paid to them. Separately, studies naming them as principal investigator received $41,110 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $25,000 across 1 holding.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 68th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $630 4
2024 General $558 5
2023 General $1,495 15
2022 General $1,961 32
2021 General $464 9
2020 General $3,006 22
2019 General $3,396 43
2019 Research $3,200 1
2024 Ownership $25,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kwan Lee
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Kwan Lee were reported at $630. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Kwan Lee Interventional Cardiology median Middle half National median
2019 $3,396 $1,097 $329–$3,048 $163
2020 $3,006 $473 $161–$1,480 $114
2021 $464 $677 $233–$1,827 $132
2022 $1,961 $978 $333–$2,724 $149
2023 $1,495 $1,136 $382–$2,986 $160
2024 $558 $1,181 $395–$3,326 $164
2025 $630 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $1,857 17 payments
  2. Medtronic, Inc. $1,629 24 payments
  3. Philips Electronics North America Corporation $1,411 10 payments
  4. Medtronic Vascular, Inc. $1,376 9 payments
  5. Corindus Inc. $1,183 5 payments
  6. Abiomed $946 14 payments
  7. ZOLL Circulation Inc $697 4 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $664 8 payments
  9. Novartis Pharmaceuticals Corporation $430 17 payments
  10. HeartFlow, Inc. $278 4 payments
  11. Other $1,037 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,209 110 payments
  2. Travel and Lodging $4,174 18 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $675 1 payment
  4. Consulting Fee $450 1 payment
Products named General payments · program years 2019–2025
  1. RESOLUTE ONYX $1,442 20 payments
  2. Edwards SAPIEN 3 Transcatheter Heart Valve $1,286 8 payments
  3. CorPath GRX $1,183 5 payments
  4. Impella $946 14 payments
  5. IGT Device Undivided $824 1 payment
  6. Resolute $700 3 payments
  7. TherOx DS2 Console $697 4 payments
  8. Downstream Cartridge $697 4 payments
  9. Catheter $697 4 payments
  10. LifeVest $664 8 payments
  11. Other $2,975 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Philips Electronics North America Corporation $3,200 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

593

Median for Cardiology: 2,533

Drug cost

$103,822

Median for Cardiology: $485,213

Branded share of claims

31.7%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 39 $40,559
Farxiga Dapagliflozin Propanediol Brand 47 $35,716
Jardiance Empagliflozin Brand 21 $20,269
Ezetimibe Generic 101 $2,715
Clopidogrel Clopidogrel Bisulfate Brand 52 $726
Atorvastatin Calcium Generic 44 $546
Rosuvastatin Calcium Generic 37 $498
Metoprolol Succinate Generic 28 $458
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 13 $444
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 16 $319

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$129,523

Medicare's payments for the services billed

Medicare patients

1,621

Average age 76

Services billed

2,423

659 women, 962 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 54%
Arthritis 50%
Atrial fibrillation 45%
Heart failure 41%
Chronic kidney disease 40%
Diabetes 34%
Cancer 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $262
$262 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

131 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record